Show simple item record

dc.contributor.authorDrosos, George C.
dc.contributor.authorVedder, Daisy
dc.contributor.authorHouben, Eline
dc.contributor.authorBoekel, Laura
dc.contributor.authorAtzeni, Fabiola
dc.contributor.authorBadreh, Sara
dc.contributor.authorBoumpas, Dimitrios T.
dc.contributor.authorBrodin, Nina
dc.contributor.authorBruce, Ian N.
dc.contributor.authorGonzález-Gay, Miguel Ángel
dc.contributor.authorJacobsen, Søren
dc.contributor.authorKerekes, György
dc.contributor.authorMarchiori, Francesca
dc.contributor.authorMukhtyar, Chetan
dc.contributor.authorRamos-Casals, Manuel
dc.contributor.authorSattar, Naveed
dc.contributor.authorSchreiber, Karen
dc.contributor.authorSciascia, Savino
dc.contributor.authorSvenungsson, Elisabet
dc.contributor.authorSzekanecz, Zoltan
dc.contributor.authorTausche, Anne-Kathrin
dc.contributor.authorTyndall, Alan
dc.contributor.authorvan Halm, Vokko
dc.contributor.authorVoskuyl, Alexandre
dc.contributor.authorMacfarlane, Gary
dc.contributor.authorWard, Michael M.
dc.contributor.authorNurmohamed, Michael T.
dc.contributor.authorTektonidou, Maria G.
dc.date.accessioned2022-05-05T23:05:19Z
dc.date.available2022-05-05T23:05:19Z
dc.date.issued2022-05-16
dc.identifier.citationDrosos , G C , Vedder , D , Houben , E , Boekel , L , Atzeni , F , Badreh , S , Boumpas , D T , Brodin , N , Bruce , I N , González-Gay , M Á , Jacobsen , S , Kerekes , G , Marchiori , F , Mukhtyar , C , Ramos-Casals , M , Sattar , N , Schreiber , K , Sciascia , S , Svenungsson , E , Szekanecz , Z , Tausche , A-K , Tyndall , A , van Halm , V , Voskuyl , A , Macfarlane , G , Ward , M M , Nurmohamed , M T & Tektonidou , M G 2022 , ' EULAR recommendations for cardiovascular risk management in Rheumatic and Musculoskeletal Diseases, including Systemic Lupus Erythematosus and Antiphospholipid Syndrome ' , Annals of the Rheumatic Diseases , vol. 81 , pp. 768-779 . https://doi.org/10.1136/annrheumdis-2021-221733en
dc.identifier.issn0003-4967
dc.identifier.otherPURE: 211247801
dc.identifier.otherPURE UUID: 165fd5b6-5140-4a58-b835-7d7918c58743
dc.identifier.otherORCID: /0000-0003-2322-3314/work/114480469
dc.identifier.otherScopus: 85125531096
dc.identifier.urihttps://hdl.handle.net/2164/18533
dc.descriptionAcknowledgements: The committee wishes to acknowledge the support of the EULAR Standing Committee on Clinical Affairs and the EULAR Secretariat. Funding: This study was funded by European Alliance of Associations for Rheumatology, EULAR. Project number: CLI112en
dc.format.extent12
dc.language.isoeng
dc.relation.ispartofAnnals of the Rheumatic Diseasesen
dc.rightsThis is the accepted version of [full cite]. Version of record can be found at [DOI]en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectRecommendationsen
dc.subjectcardiovascular diseaseen
dc.subjectrheumatic and musculoskeletal diseaseen
dc.subjecttraditional cardiovascular risk factorsen
dc.subjectdisease-related risk factorsen
dc.subjectR Medicineen
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleEULAR recommendations for cardiovascular risk management in Rheumatic and Musculoskeletal Diseases, including Systemic Lupus Erythematosus and Antiphospholipid Syndromeen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Vice Principalsen
dc.contributor.institutionUniversity of Aberdeen.Epidemiology Groupen
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Arthritis and Musculoskeletal Health (ACAMH)en
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPostprinten
dc.identifier.doihttps://doi.org/10.1136/annrheumdis-2021-221733
dc.date.embargoedUntil2022-05-06
dc.identifier.vol81en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record